You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

933 Results
Guidelines and Advice
Status: In-Review
ID: GL 5-3ORG
Version: 2
Apr 2019
Guidelines and Advice
Status: Archived
ID: 17-4
Version: 2
Nov 2016
Drug
Other Name(s): Nubeqa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2026
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    darolutamide - For the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, based on criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
pomalidomide (Unfunded),
selinexor (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
belantamab mafodotin (Compassionate),
pomalidomide (Unfunded),
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Dostarlimab - Primary Advanced or Recurrent Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dostarlimab,
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Drug
Other Name(s): Jemperli
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Mar 2026

Pages